HILDEN, Germany and GERMANTOWN, Maryland, October 12, 2017 /PRNewswire/ --
QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced that its Sample to Insight solutions, from next-generation sequencing (NGS) technologies to bioinformatics solutions for research and clinical testing, figure prominently in independent studies presented this week at the American Society of Human Genetics (ASHG) annual meeting in Orlando, Florida. The ASHG 2017 conference, from October 17-21, attracts leaders in research and clinical applications from around the world, offering scientific sessions on new technologies in molecular biology and discoveries regarding genomic influences on disease.
Click here for the full press release
https://corporate.qiagen.com/newsroom/press-releases/2017/2017-10-12-ASHG-Abstracts?sc_lang=en
Contacts: QIAGEN Investor Relations John Gilardi e-mail: [email protected] +49-2103-29-11711 Public Relations Dr. Thomas Theuringer e-mail: [email protected] +49-2103-29-11826
SOURCE Qiagen N.V.
Advertisement
QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced that its Sample to Insight solutions, from next-generation sequencing (NGS) technologies to bioinformatics solutions for research and clinical testing, figure prominently in independent studies presented this week at the American Society of Human Genetics (ASHG) annual meeting in Orlando, Florida. The ASHG 2017 conference, from October 17-21, attracts leaders in research and clinical applications from around the world, offering scientific sessions on new technologies in molecular biology and discoveries regarding genomic influences on disease.
Advertisement
Click here for the full press release
https://corporate.qiagen.com/newsroom/press-releases/2017/2017-10-12-ASHG-Abstracts?sc_lang=en
Contacts: QIAGEN Investor Relations John Gilardi e-mail: [email protected] +49-2103-29-11711 Public Relations Dr. Thomas Theuringer e-mail: [email protected] +49-2103-29-11826
SOURCE Qiagen N.V.
